Medjeral-Thomas Nicholas R, Thomson Tina, Ashby Damien, Muthusamy Anand, Nevin Margaret, Duncan Neill, Loucaidou Marina
Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
Centre for Inflammatory Disease, Imperial College London, UK.
Kidney Int Rep. 2020 Nov;5(11):2055-2065. doi: 10.1016/j.ekir.2020.08.022. Epub 2020 Aug 25.
Dialysis patients are at risk of severe coronavirus disease 2019 (COVID-19). We managed COVID-19 hemodialysis outpatients in dedicated satellite dialysis units. This provided rare opportunity to study early disease progress in community-based patients. We aimed to (i) understand COVID-19 progression, (ii) identify markers of future clinical severity, and (iii) assess associations between dialysis management strategies and COVID-19 clinical outcomes.
We conducted a cohort study of all outpatients managed at a COVID-19 hemodialysis unit. We analyzed data recorded as part of providing COVID-19 clinical care. We analyzed associations between features at diagnosis and the first 3 consecutive hemodialysis sessions in patients who required future hospital admission, and those who had died at 28 days.
Isolated outpatient hemodialysis was provided to 106 patients over 8 weeks. No patients received antiviral medication or hydroxychloroquine. Twenty-one patients (20%) were admitted at COVID-19 diagnosis; 29 of 85 patients (34%) were admitted after initial outpatient management; 16 patients (15%) died. By multivariate analysis, nonactive transplant list status, use of institutional transport, and increased white cell count associated with future hospitalization and increased age associated with death. Oxygen saturations progressively decreased over the first 3 dialysis sessions in the cohorts that progressed to future hospital admission or death. Mean ultrafiltration volume of the first 3 hemodialysis sessions was reduced in the same cohorts.
Outpatient hemodialysis in patients with COVID-19 is safe for patients and staff. Features at the first 3 dialysis sessions can identify individuals at risk of future hospitalization and death from COVID-19.
透析患者有患重症2019冠状病毒病(COVID-19)的风险。我们在专门的卫星透析单元管理COVID-19血液透析门诊患者。这为研究社区患者的早期疾病进展提供了难得的机会。我们旨在:(i)了解COVID-19的进展情况,(ii)识别未来临床严重程度的标志物,以及(iii)评估透析管理策略与COVID-19临床结局之间的关联。
我们对在一个COVID-19血液透析单元管理的所有门诊患者进行了一项队列研究。我们分析了作为提供COVID-19临床护理一部分记录的数据。我们分析了诊断时的特征与那些需要未来住院治疗的患者以及在28天内死亡的患者的前3次连续血液透析治疗之间的关联。
在8周内为106名患者提供了单独的门诊血液透析。没有患者接受抗病毒药物或羟氯喹。21名患者(20%)在COVID-19诊断时入院;85名患者中的29名(34%)在初始门诊管理后入院;16名患者(15%)死亡。通过多变量分析,非活跃移植名单状态、使用机构交通工具以及白细胞计数增加与未来住院相关,年龄增加与死亡相关。在进展为未来住院或死亡的队列中,在前3次透析治疗期间氧饱和度逐渐下降。在相同队列中,前3次血液透析治疗的平均超滤量减少。
COVID-19患者的门诊血液透析对患者和工作人员是安全的。前3次透析治疗的特征可以识别有因COVID-19未来住院和死亡风险的个体。